Technetium tc 99M oxidronate

What Technetium tc 99M oxidronate is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Technescan HDP, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for skeletal imaging to demonstrate areas of altered osteogenesis in adult and pediatric patients.

— FDA label: Technescan HDP, Curium US LLC, effective December 5, 2025. Read the full label on DailyMed →

Label quoted: the one for the most common form (injection, powder, lyophilized, for solution, intravenous), Technescan HDP, Curium US LLC; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Technetium tc 99M oxidronate side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following adverse reactions associated with the use of Technescan HDP have been reported: hypersensitivity reactions, including life-threatening reactions, as well as nausea, vomiting, and injection site reactions.

— FDA label: Technescan HDP, Curium US LLC, effective December 5, 2025. Read the full label on DailyMed →

Technetium tc 99M oxidronate drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

The biodistribution of technetium Tc 99m oxidronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality.

Read more of this section

In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m oxidronate injection once the cation levels have normalized (e.g., after 3 to 5 half-lives of the cation). (See WARNINGS.) Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate carcinogenic or mutagenic potential or whether technetium Tc 99m oxidronate affects fertility in males and females. Pregnancy Animal reproduction studies have not been conducted with technetium Tc 99m oxidronate. It is also not known whether technetium Tc 99m oxidronate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. All radiopharmaceuticals, including Tehnescan HDP, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. If considering Technescan HDP administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from technetium Tc 99m oxidronate and the gestational timing of exposure. Nursing Mothers Technetium-99m is excreted in human milk during lactation, therefore formula feedings should be substituted for breast feedings. Pediatric Use Technescan HDP, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for skeletal imaging to demonstrate areas of altered osteogenesis in pediatric patients. The relatively higher effective dose and radiation exposure of the epiphyses in growing bone should be considered in pediatric patients. (See DOSAGE AND ADMINISTRATION, Radiation Dosimetry). Geriatric Use This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

— FDA label: Technescan HDP, Curium US LLC, effective December 5, 2025. Read the full label on DailyMed →

Technetium tc 99M oxidronate dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

Radiation Safety – Drug Handling After radiolabeling of Technescan HDP, the reaction vial contains Technetium Tc 99m Oxidronate Injection. Handle Technetium Tc 99m Oxidronate Injection with appropriate safety measures to minimize radiation exposure. (See PRECAUTIONS, General.) Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling Technetium Tc 99m Oxidronate Injection.

Read more of this section

Radiopharmaceuticals should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides. Recommended Dosage Adults The recommended amount of radioactivity of Technetium Tc 99m Oxidronate Injection in adults is 555 MBq (15 mCi) with a range of 370 MBq to 740 MBq (10 mCi to 20 mCi). The maximum dose of oxidronate sodium in adults is 2 mg. Pediatric Patients The recommended amount of radioactivity of Technetium Tc 99m Oxidronate Injection in pediatric patients is 7.4 MBq/kg to 13 MBq/kg (0.20 mCi/kg to 0.35 mCi/kg). The recommended minimum and maximum activity in pediatric patients are 37 MBq (1 mCi) and 740 MBq (20 mCi), respectively. The maximum dose of oxidronate sodium in pediatric patients is 2 mg. Administration Instructions Measure the patient dose with a dose calibrator just prior to administration. Administer the dose intravenously by slow injection 1 hour to 4 hours before imaging. To minimize radiation dose to the bladder, encourage the patients to drink fluids before and after administration of Technetium Tc 99m Oxidronate Injection and to void immediately before the examination and as often thereafter as possible for the next 6 hours. (See PRECAUTIONS, General.) Directions for Drug Preparation Procedural Precautions The contents of the vial are intended only for use in the preparation of Technetium Tc 99m Oxidronate Injection and are NOT to be administered directly to the patient. The components of the kit are sterile and non-pyrogenic. Follow the directions carefully and adhere to strict aseptic procedures during preparation. Sodium pertechnetate Tc 99m injection that contains an oxidizing agent or 0.9% sodium chloride injection containing preservatives is not suitable for use in the preparation of Technetium Tc 99m Oxidronate Injection. Wear waterproof gloves during the entire preparation procedure and during subsequent patient dose withdrawals from the reaction vial. Make all transfers of sodium pertechnetate Tc 99m injection using an adequately shielded syringe. Keep the prepared Technetium Tc 99m Oxidronate Injection in the lead vial shield with fitted lead cover in place during the useful life of the radioactive preparation. Make all withdrawals and injection of the Technetium Tc 99m Oxidronate Injection with an adequately shielded syringe. If the dose is for a single adult patient or for pediatric patients, see Directions for the Preparation of a Single Adult Dose or Pediatric Dose(s).

— FDA label: Technescan HDP, Curium US LLC, effective December 5, 2025. This is part of the section. Read the full label on DailyMed →

Technetium tc 99M oxidronate in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Animal reproduction studies have not been conducted with technetium Tc 99m oxidronate. It is also not known whether technetium Tc 99m oxidronate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. All radiopharmaceuticals, including Tehnescan HDP, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.

Read more of this section

If considering Technescan HDP administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from technetium Tc 99m oxidronate and the gestational timing of exposure.

— FDA label: Technescan HDP, Curium US LLC, effective December 5, 2025. Read the full label on DailyMed →

Technetium tc 99M oxidronate and breastfeeding

Quoted from the nursing mothers / lactation part of the FDA-approved label.

Technetium-99m is excreted in human milk during lactation, therefore formula feedings should be substituted for breast feedings.

— FDA label: Technescan HDP, Curium US LLC, effective December 5, 2025. Read the full label on DailyMed →

Technetium tc 99M oxidronate overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

In the event of the administration of an overdose of Technetium Tc 99m Oxidronate Injection, encourage patients to drink fluids and void frequently to reduce the radiation dose to the patient.

— FDA label: Technescan HDP, Curium US LLC, effective December 5, 2025. Read the full label on DailyMed →

Forms and how it is given

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

• Curium US LLC1 product

FDA approval history

• NDA: New Drug Application: how a new (usually brand-name) medicine is approved.

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

Next steps

• Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
• Latest FDA drug recallsAll medicines, newest first
• Curium US LLCMaker or distributor
• All prescription drugs A to ZSearch by generic, brand or Spanish name

Sources

1. FDA-approved label on DailyMed (National Library of Medicine) — Technescan HDP, Curium US LLC, effective December 5, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers